Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07941944 · 1 trial · 1 indication
Part 1 and Part 2
Part 1 and Part 2
Part 1 and Part 2
Part 1 and Part 2
Part 3
Part 3 - if data permit
Part 3 - If AUCinf not collected
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | Single ascending dose of PF-07941944 or placebo in healthy adult participants |
| Part 2 | EXPERIMENTAL | Multiple doses of PF-07941944 or placebo in healthy adult participants |
| Part 3 (Optional) | EXPERIMENTAL | Period 1, single dose of Midazolam. Period 2, multiple doses of PF-07941944 + Midazolam |
| Name | Type | Description |
|---|---|---|
| PF-07941944 | DRUG | Oral formulation |
| Placebo | DRUG | Oral formulation |
| Midazolam | DRUG | Oral formulation |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Body mass index (BMI) of 17.5 to 30.5 kg/m2 * For inclusion of Japanese participants: participants who have 4 Japanese biologic grandparents who were born in Japan. Exclusion Criteria: * Evidence or h...
PF-07941944 is an investigational small molecule developed by Pfizer, Inc. It is in Phase 1 clinical development. The therapeutic indication has not been disclosed. One Phase 1 trial has been completed, enrolling 25 healthy adult participants in Belgium.
PF-07941944 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the completed Phase 1 study of the compound.
PF-07941944 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
PF-07941944 has been studied in one Phase 1 trial, NCT06920498, titled a study to learn how different amounts of the study medicine called PF-07941944 are tolerated in the body of healthy adults. The trial is completed and enrolled 25 healthy adult participants in Belgium.
The Phase 1 trial NCT06920498 was a controlled, randomized study that was not double blind. It enrolled 25 healthy adult volunteers of all sexes, aged 18 years and older, in Belgium. The study is completed.